4 results about "Low bone mass" patented technology

The present application provides methods of use, specifically methods of treatment of a disease, disorder, or condition (e.g, a low bone mass condition such as osteoporosis) in a human individual, comprising administration of novel bispecific antibodies that bind to both sclerostin and DKK-1 (e.g, anti-Sclerostin x anti-DKK-1 bispecific antibodies). The present application also provides methods of increasing bone mineral density in a human individual comprising administration of novel anti-Scl erostin x anti-DKK-1 bispecific antibodies. The present application further provides methods of reducing risk of bone fracture (e.g., osteoporotic fracture) in a human individual comprising administration of novel anti-Sclerostin x anti-DKK-1 bispecific antibodies.

This invention belongs to the technical field of Mongolian medicine composition, and discloses a Mongolian medicine composition for treating osteoporosis, its preparation and application. The composition, by weight, consists of 5-15 parts of ginseng, 10-20 parts of dragon bone, 8-18 parts of gypsum, 6-16 parts of pomegranate, 3-9 parts of cardamom, 4-12 parts of safflower, 2-8 parts of cinnamon, and 2-8 parts of long pepper. This Mongolian medicine composition integrates characteristic Mongolian medicines such as ginseng and gypsum, following the Mongolian medicine theory of "harmonizing cold and heat, and combining tonification and purgation." It can simultaneously act on three key pathological links: "inhibiting osteoclast activity," "promoting osteogenic differentiation," and "regulating the inflammatory microenvironment of bone tissue," achieving multi-target synergistic treatment. It not only effectively improves low bone mass but also significantly relieves bone pain, fundamentally intervening in bone metabolic imbalance and achieving a comprehensive therapeutic effect that addresses both the symptoms and the root cause.

The invention relates to a liquid pharmaceutical composition comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. Furthermore, it relates to a method of reducing the precipitation of an antibody or antigen-binding fragment thereof in a liquid pharmaceutical composition by adding methionine and cyclodextrin. Specifically. the liquid pharmaceutical composition comprises an anti-sclerostin antibody, hydroxypropyl-γ-cyclodextrin and methionine and can be used in the treatment of a bone disorder associated with at least one of the following: low bone formation, low bone density, low bone mineral content, low bone mass. low bone quality and low bone strength, and especially in the treatment of osteoporosis.Furthermore, the invention relates to a method of reducing injection site inflammation in a mammalian subject comprising administering a therapeutically effective amount of a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine.

This invention provides the application of Neoruscogenin in the preparation of anti-osteoporosis drugs, belonging to the field of pharmaceutical biotechnology. It was found that Neoruscogenin can significantly increase bone volume fraction, bone surface area to tissue volume ratio, bone mineral density, trabecular bone number, and trabecular bone thickness in osteoporotic mice, while significantly reducing trabecular bone separation; that is, Neoruscogenin can alleviate low bone mass in postmenopausal osteoporotic mice. Furthermore, Neoruscogenin treatment for 8 weeks did not significantly affect the major organs of mice, suggesting the biocompatibility of Neoruscogenin.